Gevokizumab Completed Phase 2 Trials for Autoimmune Inner Ear Disease Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01950312The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease